<DOC>
	<DOC>NCT00691028</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy, safety and pharmacokinetics of maintenance treatment with 3mg/kg, 6mg/kg or 10mg/kg of TA-650 in combination with methotrexate (MTX) after three infusions (weeks-0, 2, 6) of 3mg/kg in Rheumatoid Arthritis (RA) showing an insufficient response to MTX.</brief_summary>
	<brief_title>Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients with active RA in spite of stable dose of MTX Having received infliximab in the past Having a history of serious infection which caused hospitalization within 6 months before the registration Having an active tuberculosis Having a complication or a history of malignancy within 5 years before the registration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>Infliximab</keyword>
	<keyword>TA-650</keyword>
	<keyword>Remicade</keyword>
</DOC>